

# Iole Macchia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249122/publications.pdf>

Version: 2024-02-01

27  
papers

989  
citations

516561

16  
h-index

526166

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1449  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2022, 13, 871645.	1.5	13
2	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202.	1.3	6
3	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	1.8	8
4	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Na <sup>+</sup> ve/Memory T Cell Immunomonitoring. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	0.9	8
5	Lenalidomide improves the therapeutic effect of an interferon- $\gamma$ -dendritic cell-based lymphoma vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1791-1804.	2.0	18
6	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Oncolimmunology</i> , 2017, 6, e1317420.	2.1	137
7	Combining Type I Interferons and 5-Aza-2-Deoxycytidine to Improve Anti-Tumor Response against Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 159-169.	0.3	60
8	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	1.8	36
9	Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	33
10	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56
11	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. <i>Cancer Research</i> , 2011, 71, 3528-3539.	0.4	72
12	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8 <sup>+</sup> T Cells. <i>Human Gene Therapy</i> , 2010, 21, 1029-1035.	1.4	32
13	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P <sub>cy243</sub> . <i>Viral Immunology</i> , 2009, 22, 117-124.	0.6	18
14	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. <i>Journal of Immunology</i> , 2009, 182, 2888-2897.	0.4	65
15	Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. <i>Advances in Experimental Medicine and Biology</i> , 2009, 655, 189-242.	0.8	13
16	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. <i>Virus Research</i> , 2007, 126, 86-95.	1.1	3
17	Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. <i>Journal of Medical Primatology</i> , 2007, 36, 180-194.	0.3	17
18	Expression of CD8 $\beta$ identifies a distinct subset of effector memory CD4 <sup>+</sup> T lymphocytes. <i>Immunology</i> , 2006, 119, 232-242.	2.0	26

#	ARTICLE	IF	CITATIONS
19	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. <i>Journal of General Virology</i> , 2006, 87, 3385-3392.	1.3	11
20	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. <i>Medical Science Monitor</i> , 2006, 12, BR330-40.	0.5	9
21	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	1.7	70
22	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2003, 29, 193-208.	0.3	51
23	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	0.9	35
24	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	1.7	135
25	Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmac15 on the kinetics of SIV replication in cynomolgus monkeys. <i>Journal of Medical Primatology</i> , 2001, 30, 197-206.	0.3	15
26	Increased replication of sendai virus in morphine-treated epithelial cells: evidence for the involvement of the intracellular levels of glutathione. <i>International Journal of Immunopharmacology</i> , 1999, 21, 185-193.	1.1	17
27	Long-Lasting Protection by Live Attenuated Simian Immunodeficiency Virus in Cynomolgus Monkeys: No Detection of Reactivation after Stimulation with a Recall Antigen. <i>Virology</i> , 1999, 256, 291-302.	1.1	25